Patrick A Ott
Affiliation: New York University School of Medicine
- Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanomaPatrick A Ott
Division of Medical Oncology, New York University Cancer Institute, New York University School of Medicine, New York, NY 10016, USA
Chemotherapy 55:221-7. 2009..This phase II study evaluated the efficacy and tolerability of dacarbazine in combination with thalidomide in metastatic melanoma patients...
- Small-molecule protein kinase inhibitors and their effects on the immune system: implications for cancer treatmentPatrick A Ott
New York University Cancer Institute, Division of Medical Oncology, 160 E 34th Street, New York, NY 10016, USA
Immunotherapy 3:213-27. 2011....
- Vemurafenib and radiation therapy in melanoma brain metastasesAshwatha Narayana
Department of Radiation Oncology, New York University Langone Medical Center, 566 First Avenue HC 107, New York, NY 10016, USA
J Neurooncol 113:411-6. 2013..This retrospective study suggests that melanoma patients with brain metastases harboring BRAF mutation appear to be a distinct sub-group with a favorable response to vemurafenib and radiation therapy and acceptable morbidity...
- Enrollment in clinical trials correlates with improved survival in metastatic melanomaNagashree Seetharamu
Department of Medicine, New York University School of Medicine, New York, NY, USA
Oncology 81:403-9. 2011..The aim of our study was to identify the factors associated with long-term survival and to determine the impact of clinical trial enrollment on patient outcome...
- Ipilimumab for patients with advanced mucosal melanomaMichael A Postow
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Oncologist 18:726-32. 2013..Durable responses to ipilimumab were observed, but the overall response rate was low. Additional investigation is necessary to clarify the role of ipilimumab in patients with mucosal melanoma. ..
- Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanomaPatrick A Ott
Department of Medical Oncology, New York University School of Medicine, New York, NY, USA
Invest New Drugs 31:425-34. 2013..Although no RECIST responses were observed, the encouraging rate of SD in uveal melanoma patients indicates that it may be worthwhile to evaluate ADI-PEG 20 in this melanoma subgroup...
- Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trialPatrick A Ott
Division of Medical Oncology, NYU Cancer Institute, New York University School of Medicine, New York, NY 10016, USA
Cancer Chemother Pharmacol 71:183-91. 2013..The combination of oblimersen, a bcl-2 antisense oligonucleotide, and dacarbazine lead to superior progression-free survival in advanced melanoma patients. Albumin-bound paclitaxel (nab-paclitaxel) has single-agent activity in melanoma...
- Immune response in melanoma: an in-depth analysis of the primary tumor and corresponding sentinel lymph nodeMichelle W Ma
Ronald O Perelman Department of Dermatology, New York University School of Medicine, New York, NY, USA
Mod Pathol 25:1000-10. 2012..025) and melanoma-specific (P=0.014) survival. Our results support an assessment of local immune profiles in both the primary tumor and sentinel lymph node to help guide therapeutic decisions...
- A phase II trial of sorafenib in metastatic melanoma with tissue correlatesPatrick A Ott
Department of Medical Oncology, New York University School of Medicine, New York, New York, United States of America
PLoS ONE 5:e15588. 2010..Sorafenib monotherapy in patients with metastatic melanoma was explored in this multi-institutional phase II study. In correlative studies the impact of sorafenib on cyclin D1 and Ki67 was assessed...
- Mucosal melanomas: a case-based review of the literatureNagashree Seetharamu
NYU Cancer Institute, 160E 34th Street, New York, New York 10016, USA
Oncologist 15:772-81. 2010....
- Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgeryMaya Mathew
Department of Radiation Oncology, New York University Langone Medical Center, New York, New York 10016, USA
Melanoma Res 23:191-5. 2013..In this retrospective study, administration of ipilimumab neither increased toxicity nor improved intracerebral disease control in patients with limited brain metastases who received SRS...
- Inhibition of both BRAF and MEK in BRAF(V600E) mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC propertiesPatrick A Ott
New York University Cancer Institute, New York University School of Medicine, 522 First Avenue, SRB 1303, New York, NY, 10016, USA
Cancer Immunol Immunother 62:811-22. 2013..Targeting both MEK and BRAF has shown efficacy in BRAF(V600) mutant melanoma...
- Surgical approach to primary cutaneous melanomaPatrick A Ott
Division of Medical Oncology, Department of Medicine, New York University School of Medicine, New York University Cancer Institute, 160 East 34th Street, 9th Floor, New York, NY 10016, USA
Surg Oncol Clin N Am 20:39-56. 2011..The treating surgeon must balance preservation of oncologic principles, with optimization of functional and aesthetic outcome. This article reviews the rationale behind the surgical approach in the patient with a primary melanoma...
- A phase II trial of the epothilone B analog ixabepilone (BMS-247550) in patients with metastatic melanomaPatrick A Ott
Department of Medical Oncology, New York University Cancer Institute, New York, New York, United States of America
PLoS ONE 5:e8714. 2010....
- The efficacy of anti-PD-1 agents in acral and mucosal melanomaAlexander N Shoushtari
Melanoma and Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center, New York, New York
Cancer 122:3354-3362. 2016..The efficacy of PD-1 blockade for patients with biologically distinct melanomas arising from acral and mucosal surfaces has not been well described...
- Novel therapeutics for melanomaNagashree Seetharamu
NYU Cancer Institute, New York University Medical Center, New York, NY 10016, USA
Expert Rev Anticancer Ther 9:839-49. 2009..These novel therapeutics offer hope for this aggressive and so far largely treatment-resistant disease. In this review we will discuss some of the most promising novel therapeutic agents for advanced melanoma...
- Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanomaPatrick A Ott
Patrick A Ott and Anna C Pavlick, New York University Cancer Institute, New York, NY Omid Hamid and Peter D Boasberg, The Angeles Clinic and Research Institute, Los Angeles, CA Harriet Kluger and Mario Sznol, Yale Cancer Center, New Haven, CT Kevin B Kim and Patrick Hwu, University of Texas MD Anderson Cancer Center, Houston, TX Ronit Simantov, Elizabeth Crowley, Jennifer A Green, Thomas Hawthorne, and Thomas A Davis, Celldex Therapeutics, Hampton, NJ
J Clin Oncol 32:3659-66. 2014..This study evaluated the safety and activity of glembatumumab vedotin in patients with advanced melanoma...